Sign in

CIK 0001124105

  • Accelerated filer
  • Smaller reporting company

GYRE THERAPEUTICS, INC.

Sign in to watch
Ticker
GYRE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
562020050
Phone
+1 858-284-0115
Business address
12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO, CA, 92130
Former names
CATALYST BIOSCIENCES, INC., TARGACEPT INC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2019-08-12 Payne Fletcher Chief Financial Officer Grant or award +1,180 $6.51 $8K 3,744
2019-02-11 Payne Fletcher Chief Financial Officer Grant or award +1,002 $7.04 $7K 3,731
2019-02-04 Payne Fletcher Chief Financial Officer Exercise or conversion +1,503 $4.63 $7K 3,230
2019-02-04 Payne Fletcher Chief Financial Officer Exercise or conversion · Stock Option (Right to Buy) −1,503 73,497
2019-01-24 Payne Fletcher Chief Financial Officer Grant or award · Stock Option (Right to Buy) +38,000 38,000
2018-07-30 Payne Fletcher Chief Financial Officer Grant or award · Stock Option (Right to Buy) +25,000 25,000
2018-03-26 Payne Fletcher Chief Financial Officer Exercise or conversion +59 $4.63 $273 59
2018-03-26 Payne Fletcher Chief Financial Officer Exercise or conversion · Stock Option (Right to Buy) −59 74,941
2018-01-12 Payne Fletcher Chief Financial Officer Grant or award · Stock Option (Right to Buy) +26,000 26,000
2017-07-11 Payne Fletcher Chief Financial Officer Grant or award · Stock Option (Right to Buy) +75,000 75,000
2015-12-17 Payne Fletcher Chief Financial Officer Purchase +10,000 $2.00 $20K 25,032
2015-10-22 Payne Fletcher Chief Financial Officer Grant or award · Stock Option (Right to Buy) +28,572 28,572

Page 1 of 1 · 12 trades